Mangalam Drugs & Organics (NSE:MANGALAM) YoY EBITDA Growth: 122.66% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
47 GF Score
Price ₹34.26
GF Value ₹61.81
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics YoY EBITDA Growth?

Mangalam Drugs & Organics NSE:MANGALAM +7.16% 47 YoY EBITDA Growth is 122.66% as of Jun. 2026. GuruFocus rates NSE:MANGALAM with a GF Score™ of 47/100 and a GF Value™ of ₹61.81 (Possible Value Trap). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Mangalam Drugs & Organics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 122.66%.

Mangalam Drugs & Organics's EBITDA per Share for the three months ended in Jun. 2026 was ₹0.64.

Mangalam Drugs & Organics YoY EBITDA Growth Related Terms

Mangalam Drugs & Organics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics YoY EBITDA Growth Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.30 -47.19 -32.59 107.64 -138.92

Mangalam Drugs & Organics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -154.54 -131.78 -114.84 -153.34 122.66
NSE:MANGALAM
47GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Mangalam Drugs & Organics's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(-8.933-22.95)/ | 22.95 |
=-138.92 %

Mangalam Drugs & Organics's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.641--2.829)/ | -2.829 |
=122.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 122.66% mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a YoY EBITDA Growth of 122.66% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' YoY EBITDA Growth too high?
Mangalam Drugs & Organics' current YoY EBITDA Growth is 122.66%. Overall, Mangalam Drugs & Organics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' YoY EBITDA Growth compare to ZTS?
Mangalam Drugs & Organics' YoY EBITDA Growth of 122.66% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current YoY EBITDA Growth is 122.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹61.81, compared to a current price of ₹34.26 — trading 44.6% below its estimated fair value. The current YoY EBITDA Growth is 122.66%. Mangalam Drugs & Organics' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current YoY EBITDA Growth is 122.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹34.26 is trading 44.6% below its estimated GF Value™ of ₹61.81. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • YoY EBITDA Growth: 122.66%
  • GF Value™: ₹61.81 vs. price of ₹34.26 (44.6% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
47GF Score

Get the complete analysis for NSE:MANGALAM

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹34.26
Price
₹61.81
GF Value